Lindsay Rosenwald Biography | Life Facts Of Lindsay Rosenwald

OpusPoint Partners through the guidance of its co-founders, Michael Weiss and Lindsay Rosenwald, M.D., are indisputably bringing about transformational biotechnology and life science companies to the forefront. The company’s investment in and mentoring of these budding biotech companies is the first step in making new discoveries that will make waves in the healthcare sector and ultimately lead to the betterment of human health.

Dr. Rosenwald and Weiss founded OpusPoint Partners in 2009. Since the company’s inception the two men have been leading the way in biotech backing and mentoring. Both Rosenwald and Weiss are thoroughly competent in commencing, guiding, and funding life science and biotech companies as they have, individual from each other, pulled together numerous research biotech companies over the span of 20 years. It is their goal to ensure that those upcoming companies that show a spark for innovation get the opportunity to truly make their mark in the medical industry.

Lindsay Rosenwald has showcased his zeal for taking biotechnology beyond its current barriers in order to make significant progress toward changing the state of illness in the world through his previous development of Cougar Biotechnology Inc. This Los Angeles based biotech company’s main research concern is in the realms of cancer trials and treatment. Many of the findings and drug trials done by this biotech company have gained the respect and attention from researchers and investors alike. The companies most significant drug development was a potentially lifesaving drug that has shown promise in assisting those with in the later stages of prostate cancer. In 2009 Rosenwald moved on from Cougar Biotech and the company was acquired by Johnson & Johnson for nearly one billion dollars.

OpusPoint Partners has maintained its success since its inception; this is largely due to the company’s consistent policy toward sustaining its firm foundation of integrity. Lindsay Rosenwald fully comprehends the needs of investors, and places ethical business practices as priority when dealing with emergent biotech and life sciences companies. Transparency on all ends leads way to confident investing by individuals and corporations, and gives OpusPoint Partners an air of quality professionalism that is unmatched.

Since OpusPoint Partners is a biotech investing company built on the groundwork of ethical principles, it is viewed as a trusted company in which a variety of investors and researchers are clamoring to get involved with. Growth at OpusPoint Partners over the past two years has been exponential; currently the company is acting both as a mentor and as a financial force behind more than 20 budding biotech companies. With the aid of Dr. Lindsay Rosenwald these promising companies will be able to realize their medical research goals and quite possible make a monumental discovery for humanity.

Those intertwined with OpusPoint Partners goals can rest assure that their financial and advisory needs will be acknowledged. With Lindsay Rosenwald heading up the company investors feel secure about the dealings as Rosenwald is committed to providing honest analysis of ventures and offers investors minimized investing risks. OpusPoint Partners knack for investment growth is strongly evident in the company track record of exceeding yearly projections.

Dr. Lindsay Rosenwald makes OpusPoint Partners what it is today; the company is an embodiment of his skills, morals, and goals. Rosenwald’s educational background is ideally suited to what he is currently doing in his professional life. He has a B.S. in Finance from Pennsylvania State University and a M.D. from Temple University School of Medicine. In the past Rosenwald has successfully utilized his academic knowledge in two separate fields, biotechnology and Wall Street financing. In the past 17 years he has been the driving force behind the development and financing of more than 50 biotech companies.

Dr. Rosenwald is also a skilled money manager having managed the assets of both the Aries Fund (1994 to 2007) and the Orion Fund (2002 to 2006.) During the 2000 year alone he managed the allocation of investment funds over one billion dollars for the Aries Fund, this money alone was for investment in healthcare. The Orion Fund, which is dedicated to raising funds for the biotechnology industry also prospered with Lindsay Rosenwald’s assistance.

The central focus of OpusPoint Partners is to bring about innovations within the medical and healthcare industries by way of promoting biotech and life science firms who have a pioneering spirit mixed with sound ethical practices. This company stands above many others like it because of its ground-breaking ideals and strong commitment to integrity above profit. It is not hard in the medical and pharmaceutical world to find individuals who are not afraid to smudge the line of decency in order to reap excessive monetary rewards; OpusPoint Partners is a beacon of light among the crowd whose steadfast honesty in business dealings garner them much respect in the biotechnology sphere.

With Lindsay Rosenwald acting as a strong moral compass for OpusPoint Partners, the continued success of this life science and biotech investment company is unquestionable. This is because at all levels of the company, from the co-founders, employees, investors, and the associated biotech companies all adhere to the ethical standards set forth by OpusPoint Partners.

Beyond the exceptional moral business standards that both Michael Weiss and Dr. Lindsay Rosenwald continually sustain at OpusPoint Partners, they also bring a vast amount of combined experience to the company. Together the pair has in excess of 40 years working in the biotechnology and life science sectors. During the time previous to venturing on their combined business endeavor of OpusPoint Partners, both men individually have started up and found investors for a multitude of their own biotechnology companies.

The over 20 emergent biotechnology companies currently backed by OpusPoint Partners are under knowledgeable guidance from Lindsay Rosenwald. Over the first two years of OpusPoint Partners existence their roster of investors and biotech companies has grown steadily and more quickly than initially projected. This growth has produced positive returns to investors and has allowed OpusPoint Partners to make great strides in the area of medicine research and trials.

Lindsay Rosenwald maintains his activity in the biotechnology financing world in order to bring new investor into the fold and expand the reach of OpusPoint Partners. He currently sits on the Board of Directors for the Republican Jewish Coalition.

OpusPoint Partners:
Investing in the Future ofHealthcare and Life Sciences

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology.  By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals.  Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses.  Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.

For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money.  It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone.  This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

OpusPoint Partners is an innovative new company with a unique vision for the future of the life science and healthcare industry. That vision includes some cutting edge technologies but also some forward thinking business philosophies.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.